ADPT Adaptive Biotechnologies Corp

$14.38

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/6/2025

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.

Website: https://www.adaptivebiotech.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1478320
Address
1551 EASTLAKE AVENUE EAST SUITE 200, SEATTLE, WA, US
Valuation
Market Cap
$1.09B
P/E Ratio
nan
PEG Ratio
0.00
Price to Book
5.37
Performance
EPS
$-1.08
Dividend Yield
—
Profit Margin
-89.10%
ROE
-62.50%
Technicals
50D MA
$7.87
200D MA
$5.95
52W High
$9.01
52W Low
$2.36
Fundamentals
Shares Outstanding
149M
Target Price
$9.71
Beta
1.73

ADPT EPS Estimates vs Actual

● Estimated
● Actual

ADPT News & Sentiment

Sep 30, 2025 • Benzinga SOMEWHAT-BULLISH
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Robo.ai ( NASDAQ:AIIO ) , Adaptive Biotechnologies ( NASDAQ:ADPT )
U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Tuesday. Shares of United Natural Foods, Inc. ( NYSE:UNFI ) rose sharply during Tuesday's session after the company reported better-than-expected fourth-quarter EPS and sales and issued FY26 EPS guidance above ...
Sep 26, 2025 • Zacks Commentary NEUTRAL
LLY Gets EU Approval for Alzheimer's Drug & FDA Nod to Cancer Therapy
Eli Lilly secures EU approval for Alzheimer's drug Kisunla and gains FDA nod to breast cancer therapy Inluriyo.
Sep 26, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Are Medical Stocks Lagging Adaptive Biotechnologies ( ADPT ) This Year?
Here is how Adaptive Biotechnologies (ADPT) and Biorestorative Therapies, Inc. (BRTX) have performed compared to their sector so far this year.
Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
CRSP & Sirius Begin Dosing in Thromboembolic Disorder Study in EU
CRISPR Therapeutics and Sirius dose the first patient in a phase II study of SRSD107 for thromboembolic disorders in Europe.
Sep 19, 2025 • Zacks Commentary NEUTRAL
NTLA Completes Enrollment in Pivotal Study on HAE Candidate, Stock Up
Intellia shares surge nearly 30% as the company completes enrollment in its pivotal phase III HAELO study on lonvo-z for hereditary angioedema.
Sep 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Sentiment Snapshot

Average Sentiment Score:

0.279
50 articles with scored sentiment

Overall Sentiment:

Bullish

ADPT Reported Earnings

May 05, 2025
Mar 31, 2025 (Pre market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $-0.34
  • Whisper: —
  • Surprise %: 0.0%
Feb 12, 2025
Dec 31, 2024 (Pre market)
0.01 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.24
  • Whisper: —
  • Surprise %: 5.2%
Nov 07, 2024
Sep 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.29
  • Whisper: —
  • Surprise %: 24.1%
Aug 01, 2024
Jun 30, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.31
  • Estimate: $-0.33
  • Whisper: —
  • Surprise %: 6.1%
May 07, 2024
Mar 31, 2024 (Post market)
0.01 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.34
  • Whisper: —
  • Surprise %: 2.9%
Feb 14, 2024
Dec 31, 2023 (Post market)
0.03 Surprise
  • Reported EPS: $-0.30
  • Estimate: $-0.33
  • Whisper: —
  • Surprise %: 9.1%
Nov 09, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.35
  • Estimate: $-0.34
  • Whisper: —
  • Surprise %: -2.9%
Aug 02, 2023
Jun 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $-0.33
  • Estimate: $-0.35
  • Whisper: —
  • Surprise %: 5.7%
May 03, 2023
Mar 31, 2023 (Post market)
-0.02 Surprise
  • Reported EPS: $-0.40
  • Estimate: $-0.38
  • Whisper: —
  • Surprise %: -5.3%

Financials